These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 28060449

  • 1. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
    Ohta Y, Darwish M, Hishikawa N, Yamashita T, Sato K, Takemoto M, Abe K.
    Geriatr Gerontol Int; 2017 Nov; 17(11):1843-1848. PubMed ID: 28060449
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [Abstract] [Full Text] [Related]

  • 5. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
    Matsuzono K, Yamashita T, Ohta Y, Hishikawa N, Sato K, Kono S, Deguchi K, Nakano Y, Abe K.
    J Alzheimers Dis; 2015 Feb; 46(3):687-93. PubMed ID: 26402513
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J, Morgan S, Walker Z.
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
    Wattmo C, Wallin AK, Minthon L.
    BMC Neurol; 2012 Nov 05; 12():134. PubMed ID: 23126532
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.
    Arch Gerontol Geriatr Suppl; 2004 Nov 05; (9):297-307. PubMed ID: 15207427
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A, Vergara J, Leon-Colombo T, Febrer L, Rejas-Gutierrez J.
    Rev Neurol; 2004 Nov 05; 43(8):449-53. PubMed ID: 17033976
    [Abstract] [Full Text] [Related]

  • 15. Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
    Hishikawa N, Fukui Y, Sato K, Ohta Y, Yamashita T, Abe K.
    Geriatr Gerontol Int; 2017 Oct 05; 17(10):1384-1391. PubMed ID: 27578455
    [Abstract] [Full Text] [Related]

  • 16. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C, Minthon L, Wallin ÅK.
    Alzheimers Res Ther; 2016 Feb 17; 8():7. PubMed ID: 26883213
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A, Svensson AL.
    Drug Saf; 1998 Dec 17; 19(6):465-80. PubMed ID: 9880090
    [Abstract] [Full Text] [Related]

  • 20. Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
    Matsuzono K, Sato K, Kono S, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Nakano Y, Abe K.
    J Alzheimers Dis; 2015 Dec 17; 48(3):757-63. PubMed ID: 26402119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.